McDonalds Trading Volume Drops 21.85% Ranking 97th in Daily Volume

On June 12, 2025, McDonald's (MCD) saw a trading volume of $780 million, marking a 21.85% decrease from the previous day. The stock ranked 97th in terms of trading volume for the day. McDonald's stock price increased by 0.48%, marking the second consecutive day of gains, with a total increase of 0.91% over the past two days.

Morgan Stanley has advised investors to be cautious about McDonald's, citing structural pressures in the fast-food industry that the company may not be insulated from. The firm downgraded McDonald's stock to Equal-Weight, noting that the company's premium valuation no longer aligns with its weakening pricing power.

McDonald's has been a subject of interest for investors, with the stock being one of the most searched on Zacks.com. Over the past month, McDonald's shares have underperformed the broader market, with a return of -1.9% compared to the Zacks S&P 500 composite's +6.6% change. The Zacks Retail - Restaurants industry, which McDonald's is a part of, has gained 3.4% during the same period.

Earnings estimates for McDonald's have been revised, with the current quarter's expected earnings per share at $3.14, indicating a 5.7% increase from the year-ago quarter. The consensus earnings estimate for the current fiscal year is $12.25, indicating a 4.5% year-over-year change. For the next fiscal year, the consensus earnings estimate is $13.19, indicating a 7.8% change from the previous year.

McDonald's reported revenues of $5.96 billion in the last reported quarter, representing a year-over-year change of -3.5%. The company's earnings per share (EPS) for the same period was $2.67, compared to $2.7 a year ago. The reported revenues represent a surprise of -2.12% compared to the Zacks Consensus Estimate of $6.08 billion, while the EPS surprise was +1.14%.

KeyCorp raised their target price on McDonald's shares from $335.00 to $340.00 and gave the company an "overweight" rating. However, analysts have expressed concerns that weight-loss drugs like Ozempic could curb fast-food demand, potentially impacting McDonald's stock price.